Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 2,515 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Healthy
Interventions: clopidogrel, placebo, omeprazole; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Diffuse and Focal Abnormalities of the Liver and Pancreas
Interventions: Body MR imaging; Device
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Omaha, Nebraska

Conditions: Stress, Resilience, Quality of Life, Depressive Symptoms, Anxiety, Sleep, Physical Activity
Interventions: virtual reality; Device
Lead sponsor: City University of New York, School of Public Health; Other
Eligibility: 18 Years to 29 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C
Interventions: Eltrombopag, Lopinavir/Ritonavir, Eltrombopag and Lopinavir/Ritonavir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: Vayarin®, Placebo; Other
Lead sponsor: Enzymotec; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 4
States / cities: Marietta, Georgia • Mount Kisco, New York • New York, New York

Conditions: Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure, Heart Disease
Interventions: Beta blockers; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 65 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Transplants
Interventions: Intervention 1 - SRTR (age question 1st), Intervention 2 - SRTR (BMI question 1st), Intervention 3 - TCST (age question 1st), Intervention 4 - TCST (BMI question 1st); Other
Lead sponsor: Ajay Israni, MD; Other
Eligibility: 18 Years and older
Enrollment: 268 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Acute Lymphoid Leukemia, Leukemia, Acute Lymphoblastic, Multiple Myeloma, Myelofibrosis
Interventions: Molecular diagnostic testing; Genetic
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Advanced Cancer, Solid Tumors, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
Interventions: FN-1501; Drug
Lead sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Fairway, Kansas • Detroit, Michigan

Conditions: Pulmonary Nodules
Interventions: Linear EBUS first, Robotic-assisted bronchoscopy first; Diagnostic Test
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: Sacramento, California • Chicago, Illinois • Baltimore, Maryland + 2 more

Conditions: Neoplasms, Neoplasms, Ovarian, Neoplasms, Breast, Advanced or Refractory Solid Malignancies
Interventions: DOXIL/CAELYX (doxorubicin) Treatment Sequence AB, DOXIL/CAELYX (doxorubicin) Treatment Sequence BA; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Nashville, Tennessee • San Antonio, Texas

Conditions: PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Injury, Depression - Major Depressive Disorder, Suicidal Ideation
Interventions: Magnetic e-Resonance Therapy (MeRT), Ibogaine Hydrochloride with Magnesium Sulfate, 5-methoxy-N,N-dimethyltryptamine, Physiological Supplementation; Device · Drug
Lead sponsor: Axial Therapeutic Research; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Northridge, California

Conditions: Healthy Participants
Interventions: Vimseltinib, Rosuvastatin; Drug
Lead sponsor: Deciphera Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Visual Acuity
Interventions: Blink® Tears eye drops in a multidose bottle, Preservative-free investigational lubricating eye drops in a Novelia® eyedropper; Drug
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 3
States / cities: Jacksonville, Florida • Maitland, Florida • Tyler, Texas

Conditions: Thyroid Nodule
Interventions: SWUS Elastography; Device
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Aspirin 81mg, Aspirin 162 mg, Aspirin 325mg; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 40 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hiv, Pregnancy Related
Interventions: Impact of ring size on adherence; Device
Lead sponsor: Population Council; Other
Eligibility: 18 Years to 40 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Atlanta, Georgia • New York, New York

Conditions: Healthy
Interventions: Lenalidomide, Quinidine, Temsirolimus, Diphenhydramine; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: warfarin; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Stroke
Interventions: Hip Hop Stroke educational program, Nutrition Education program; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 7 Years and older
Enrollment: 4,614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: UCB0022; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy
Interventions: lesinurad/allopurinol 200/300 FDC tablets, lesinurad 200 mg, allopurinol 300 mg, lesinurad/allopurinol 200/200 FDC tablets, allopurinol 200 mg; Drug
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Tuberculosis
Interventions: PA-824 200mg, PA-824 50mg; Drug
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 19 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Whole Genome Sequencing
Interventions: Genetic Counselor, Trained Healthcare Provider; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: Not listed
Enrollment: 477 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Birmingham, Alabama • Baton Rouge, Louisiana • Jackson, Mississippi

Search by objective public record fields.

Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects

Abdominal MR Imaging at 3.0T: Sequence Optimization and Implementation

Virtual Reality (VR) for Stress Management

Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.

Vayarin® Medical Food Study for Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF

Creating a Patient-centered Report Card for Solid Organ Transplant Candidates

iCare for Cancer Patients

A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML

The SEQUENCE Trial

A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer

Trifecta Research Study

Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate

Clinical Investigation of Visual Acuity in Contact Lens Wearers After Instillation of Investigational Lubricating Eye Drops

Shear Wave Ultrasound Elastography in Noninvasive Diagnosis of Thyroid Nodules

Trial to Determine Effective Aspirin Dose in COPD

A Crossover Study Evaluating 3 Non-medicated Silicone IVRs

Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males

Warfarin and Vatalanib in Treating Patients With Advanced Solid Tumors

Effect of Intervention to Improve Stroke Recognition

A Phase 1 Relative Bioavailability Study of UCB0022 Tablets in Healthy Participants

Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability

Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects (CL-009)

South-seq: Deoxyribonucleic Acid (DNA) Sequencing for Newborn Nurseries in the South